FDA First-Generic Notification Policy May Be Reviewed
Executive Summary
FDA will re-examine whether it is legally barred from notifying a generic company early in the ANDA process that it is the first filer eligible for 180-day exclusivity, Chief Counsel Dan Troy said Sept. 30
You may also be interested in...
Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes
U.S. FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.
Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes
FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.
U.S. Generic Exclusivity Process To Go Public?
The U.S. FDA wants to know whether its 180-day generic exclusivity process should be revealed up front; the question will be one of many on ANDA reviews to be considered at a September public hearing.